Proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients

Autoři: Sayaka Maeda aff001;  Makoto Yamaguchi aff002;  Kunihiro Maeda aff001;  Naoto Kobayashi aff001;  Naoki Izumi aff001;  Masaaki Nagai aff001;  Takaaki Obayashi aff001;  Wataru Ohashi aff003;  Takayuki Katsuno aff002;  Hironobu Nobata aff002;  Yasuhiko Ito aff002
Působiště autorů: Department of Nephrology, Narita Memorial Hospital, Toyohashi, Japan aff001;  Department of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan aff002;  Division of Biostatistics, Clinical Research Center, Aichi Medical University, Nagakute, Japan aff003
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0224859


Peritonitis is a major and the most significant complication of peritoneal dialysis (PD). Although some predictors of peritonitis in PD patients are known, the association between proton pump inhibitor (PPI) use and peritonitis has not been characterized. Here, we examined whether PPI use is a risk factor for the development of peritonitis, based on a single-center retrospective analysis of 230 consecutive Japanese PD patients at Narita Memorial Hospital. We assessed the association between PPI use and subsequent first episode of peritonitis using multivariate Cox proportional hazards models, following adjustment for clinically relevant factors. The median follow-up period was 36 months (interquartile range, 19–57 months). In total, 86 patients (37.4%) developed peritonitis. Analysis with multivariate Cox proportional hazards models revealed the following significant predictors of peritonitis: PPI use (adjusted hazard ratio [HR] = 1.72, 95% confidence interval [CI]: 1.11–2.66; P = 0.016) and low serum albumin level (per g/dl adjusted HR = 0.59, 95% CI: 0.39–0.90; P = 0.014). Thus, PPI use was independently associated with PD-related peritonitis. The results suggest that nephrology physicians should exercise caution when prescribing PPIs for PD patients.

Klíčová slova:

Effluent – Medical dialysis – Medical risk factors – Peritonitis – Serum albumin – Proton pumps


1. Voinescu CG, Khanna R. Peritonitis in peritoneal dialysis. Int J Artif Organs. 2002;25: 249–260. doi: 10.1177/039139880202500402 12027134

2. Li PK, Szeto CC, Piraino B, de Arteaga J, Fan S, Figueiredo AE, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36: 481–508. doi: 10.3747/pdi.2016.00078 27282851

3. Yip T, Tse KC, Lam MF, Cheng SW, Lui SL, Tang S, et al. Risks and outcomes of peritonitis after flexible colonoscopy in CAPD patients. Perit Dial Int. 2007;27: 560–564. 17704448

4. Poortvliet W, Selten HP, Raasveld MH, Klemt-Kropp M. CAPD peritonitis after colonoscopy: follow the guidelines. Neth J Med. 2010;68: 377–378. 20919445

5. Machuca E, Ortiz AM, Rabagliati R. Streptococcus viridans-associated peritonitis after gastroscopy. Adv Perit Dial. 2005;21: 60–62. 16686285

6. Cho Y, Johnson DW. Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. Am J Kidney Dis. 2014;64: 278–289. doi: 10.1053/j.ajkd.2014.02.025 24751170

7. Prasad N, Gupta A, Sharma RK, Sinha A, Kumar R. Impact of nutritional status on peritonitis in CAPD patients. Perit Dial Int. 2007;27: 42–47. 17179509

8. Wang Q, Bernardini J, Piraino B, Fried L. Albumin at the start of peritoneal dialysis predicts the development of peritonitis. Am J Kidney Dis. 2003;41: 664–669. doi: 10.1053/ajkd.2003.50128 12612991

9. Troidle L, Watnick S, Wuerth DB, Gorban-Brennan N, Kliger AS, Finkelstein FO. Depression and its association with peritonitis in long-term peritoneal dialysis patients. Am J Kidney Dis. 2003;42: 350–354. doi: 10.1016/s0272-6386(03)00661-9 12900818

10. Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother. 2007;51: 2883–2887. doi: 10.1128/AAC.01443-06 17562803

11. Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, Deshpande N, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012;10: 225–233. doi: 10.1016/j.cgh.2011.09.030 22019794

12. Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 1998;28: 1187–1190. doi: 10.1002/hep.510280504 9794900

13. Chang SS, Lai CC, Lee MT, Lee YC, Tsai YW, Hsu WT, et al. Risk of spontaneous bacterial peritonitis associated with gastric acid suppression. Medicine (Baltimore). 2015;94: e944. doi: 10.1097/MD.0000000000000944 26039135

14. Min YW, Lim KS, Min BH, Gwak GY, Paik YH, Choi MS, et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment Pharmacol Ther. 2014;40: 695–704. doi: 10.1111/apt.12875 25078671

15. Zhong HJ, Lin D, Lu ZY, Yang WY, Chen Y. Use of gastric-acid suppressants may be a risk factor for enteric peritonitis in patients undergoing peritoneal dialysis: a meta-analysis. J Clin Pharm Ther. 2019;44: 209–215. doi: 10.1111/jcpt.12769 30332507

16. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53: 982–992. doi: 10.1053/j.ajkd.2008.12.034 19339088

17. Keane WF, Alexander SR, Bailie GR, Boeschoten E, Gokal R, Golper TA, et al. Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. Perit Dial Int. 1996;16: 557–573. 8981523

18. Ciz M, Lojek A. Modulation of neutrophil oxidative burst via histamine receptors. Br J Pharmacol. 2013;170: 17–22. doi: 10.1111/bph.12107 23336732

19. Frei R, Ferstl R, Konieczna P, Ziegler M, Simon T, Rugeles TM, et al. Histamine receptor 2 modifies dendritic cell responses to microbial ligands. J Allergy Clin Immunol. 2013;132: 194–204. doi: 10.1016/j.jaci.2013.01.013 23465664

20. Takagi T, Naito Y, Inoue R, Kashiwagi S, Uchiyama K, Mizushima K, et al. The influence of long-term use of proton pump inhibitors on the gut microbiota: an age-sex-matched case-control study. J Clin Biochem Nutr. 2018;62: 100–105. doi: 10.3164/jcbn.17-78 29371761

21. Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65: 740–748. doi: 10.1136/gutjnl-2015-310376 26657899

22. Pérez-Fontan M, Machado Lopes D, García Enríquez A, López-Calviño B, López-Muñiz A, García Falcón T, et al. Inhibition of gastric acid secretion by H2 receptor antagonists associates a definite risk of enteric peritonitis and infectious mortality in patients treated with peritoneal dialysis. PLoS One. 2016;11: e0148806. doi: 10.1371/journal.pone.0148806 26872254

23. Chen L, Zhang YH, Huang T, Cai YD. Gene expression profiling gut microbiota in different races of humans. Sci Rep. 2016;6: 23075. doi: 10.1038/srep23075 26975620

24. Kwon JE, Koh SJ, Chun J, Kim JW, Kim BG, Lee KL, et al. Effect of gastric acid suppressants and prokinetics on peritoneal dialysis-related peritonitis. World J Gastroenterol. 2014;20: 8187–8194. doi: 10.3748/wjg.v20.i25.8187 25057226

25. Keane WF, Swan SK, Grimes I, Humphries TJ. Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure. J Clin Pharmacol. 1999;39: 927–933. doi: 10.1177/00912709922008542 10471983

26. Sica DA, Comstock T, Harford A, Eshelman F. Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol. 1987;32: 587–591. doi: 10.1007/bf02455993 3653228

27. Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology (Baltimore, MD). 1998;28: 1187–1190.

28. Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine. Gut. 1996;39: 54–59. doi: 10.1136/gut.39.1.54 8881809

29. Takahashi Y, Amano Y, Yuki T, Ose T, Miyake T, Kushiyama Y, et al. Influence of acid suppressants on gastric emptying: cross-over analysis in healthy volunteers. J Gastroenterol Hepatol. 2006;21: 1664–1668. doi: 10.1111/j.1440-1746.2006.04270.x 16984586

30. Brooks AW, Priya S, Blekhman R, Bordenstein SR. Gut microbiota diversity across ethnicities in the United States. PLoS Biol. 2018;16: e2006842. doi: 10.1371/journal.pbio.2006842 30513082

31. van Diepen AT, Tomlinson GA, Jassal SV. The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients. Clin J Am Soc Nephrol. 2012;7: 1266–1271. doi: 10.2215/CJN.00980112 22745277

Článek vyšel v časopise


2019 Číslo 11